Phenotypic analysis of 1-B-D-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response.

doi:10.1007/BF00686404

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Phenotypic analysis of 1-B-D-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response.

Cancer chemotherapy and pharmacology - 1 Jan 1992

Kreis W, Lesser M, Budman D R, Arlin Z, DeAngelis L, Baskind P, Feldman E J, Akerman S

Abstract excerpt

Two phenotypes for 1-B-D-arabinofuranosylcytosine (ara-C) deamination corresponding to a ratio of distribution for "slow" (ratio, less than or equal to 14) vs "fast" (ratio, greater than 14) deaminators of 70%:30%, have been determined on the basis of studies on plasma ratios of 1-B-D-arabinofura...

Topics

Adolescent
Adult
Aged
Aged, 80 and over
Arabinofuranosyluracil
Cytarabine
Deamination
Dose-Response Relationship, Drug
Female
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Leukemia, Myeloid, Acute

Leukocyte Count

Male

Middle Aged

Phenotype

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Serum Albumin, Bovine

Source

Open in PubMed

Identifiers

PMID: 1600592
DOI: 10.1007/BF00686404

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-1600592-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Phenotypic analysis of 1-B-D-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response.PMID 1600592Read ↗

Influence of anticancer therapy on oxidation phenotype and acetylation phenotype in patients with acute myeloblastic leukemia.Semantic proximity Read ↗

Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-beta-D-arabinofuranosylcytosine.Semantic proximity Read ↗

Comparison of antineoplastic activity of cytosine arabinoside and 5-aza-2'-deoxycytidine against human leukemic cells of different phenotype.Semantic proximity Read ↗

Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.Semantic proximity Read ↗

Resistance to cytosine arabinoside in cells transfected with activated Ha-ras oncogene.Semantic proximity Read ↗

Paradoxical relationship between acetylator phenotype and amonafide toxicity.Semantic proximity Read ↗

Susceptibility to cytosine arabinoside (Ara-C)-induced cytotoxicity in human leukemia cell linesSemantic proximity Read ↗

Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.